COGT Projected Dividend Yield
Cogent Biosciences Inc ( NASDAQ : COGT )Cogent Biosciences, Inc. is a biotechnology company. Co. is focused on developing precision therapies for genetically defined diseases. Co.'s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Co. is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3K?. 21 YEAR PERFORMANCE RESULTS |
COGT Dividend History Detail COGT Dividend News COGT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |